Azurix, 120 mg 30 pcs

Uric acid is the end product of purine metabolism in humans and is formed by the following reaction: hypoxanthine → xanthine → uric acid. Xanthine oxidase is a catalyst for both steps of this reaction. Febuxostat is a 2-arylthiazole derivative. Its therapeutic effect is associated with reduction of serum uric acid concentration by selective inhibition of xanthine oxidase. Febuxostat is a potent and selective non-purine xanthine oxidase inhibitor (NP-SIXO), its inhibition constant (Ki) is <1 nM. Febuxostat was shown to significantly inhibit the activity of both oxidized and reduced forms of xanthine oxidase. At therapeutic concentrations, febuxostat does not affect other enzymes involved in purine or pyrimidine metabolism, such as guanine deaminase, hypoxanthineguanine phosphoribosyltransferase, orotidine monophosphate decarboxylase or purine nucleoside phosphorylase.Clinical effectiveness and safety:

Indications

Treatment of chronic hyperuricemia in patients with diseases accompanied by deposits of urate crystals, including the presence of tophi and/or gouty arthritis in the present or in the history.

Active ingredient

Febuxostat

How to take, the dosage

Gout. The recommended dose of Azurix is 80 mg once daily orally, regardless of meals. If serum uric acid concentration exceeds 6 mg/dL (357 µmol/L) after 2-4 weeks of treatment, the Azurix dose can be increased to 120 mg once daily.

Interaction

Mercaptopurine/azathioprine. According to the mechanism of action of febuxostat consisting in the ability to inhibit xanthine oxidase, its simultaneous use with mercaptopurine/azathioprine is not recommended. Inhibition of xanthine oxidase may lead to increased plasma concentrations of both drugs, which may cause a toxic reaction. Studies of interaction of febuxostat with drugs that are metabolized by xanthine oxidase have not been conducted.

Contraindications

Hypersensitivity to the active substance or any other excipient of the drug.

Side effects

The most common adverse reactions in clinical trials (4072 patients using doses from 10 to 300 mg) and in post-marketing follow-up in patients with gout were gout exacerbations (attacks), liver dysfunction, diarrhea, nausea, headache, rashes, and edema. These reactions were mostly mild to moderate in severity. During post-marketing surveillance, there were reports of serious hypersensitivity reactions to febuxostat, some of them accompanied by systemic reactions.

Overdose

In case of overdose, symptomatic and supportive therapy is indicated.

Similarities

Adenuric, Febuxostat NW